ELI LILLY AND COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,856 MXN | +0.29% |
|
+2.05% | +40.19% |
| Sales 2024 * | 42.98B 730B 3,373B | Sales 2025 * | 52.62B 894B 4,130B | Capitalization | 739B 12,550B 57,973B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 203B 937B | Net income 2025 * | 16.55B 281B 1,299B | EV / Sales 2024 * | 17.6 x |
| Net Debt 2024 * | 18.07B 307B 1,418B | Net Debt 2025 * | 15B 255B 1,177B | EV / Sales 2025 * | 14.3 x |
| P/E ratio 2024 * |
61.4
x | P/E ratio 2025 * |
44.2
x | Employees | 43,000 |
| Yield 2024 * |
0.63% | Yield 2025 * |
0.73% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +0.29% | ||
| 1 week | +2.05% | ||
| 1 month | +3.88% | ||
| 3 months | +8.20% | ||
| 6 months | +34.80% | ||
| Current year | +40.19% |
1 week
13 720.00
13 912.00
1 month
12 477.0013 912.00
Current year
9 980.0013 912.00
1 year
7 452.7513 912.00
3 years
3 952.9913 912.00
5 years
1 970.0013 912.00
10 years
743.6713 912.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 31/12/00 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 13,856 | +0.29% | 192 |
| 30/05/24 | 13,816 | +0.70% | 160 |
| 29/05/24 | 13,720 | +1.05% | 644 |
| 24/05/24 | 13,578 | +1.82% | 22 |
End-of-day quote Mexican S.E., May 30, 2024
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B | |
| -.--% | 122B |
- Stock Market
- Equities
- LLY Stock
- LLY * Stock
